Authorization

SANUWAVE Announces Attendance at the 5th Annual Innovations In Wound Healing Symposium, Key West, December 6-9, 2018

SUWANEE, GA, Dec. 07, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --A SANUWAVE Health, Inc. (OTCQB: SNWV)A SANUWAVE is excited to announce attendance at the 5th annualA Innovations In Wound Healing SymposiumA in Key West, Florida on December 6-9.A  The symposium topics are based on innovations in wound healing and tailored for clinicians, scientists and industry colleagues committed to developing new approaches in tissue regeneration to new treatments for chronic and complex wounds.A Innovations In Wound HealingA will offer a spectrum of presentations that extend from molecular biology to clinical development in both healing and fibrosis, allowing participants to gain a broader perspective of the challenges of moving basic science discovery into new product development and improved patient care. A 
Shri Parikh, President of SANUWAVE stated, a??We are honored to participate at this yeara??sA Innovations In Wound HealingSymposium.A There is a worldwide prevalence of nearly 200 million skin wounds and this forum offers a great opportunity for the sharing and advancement of innovative ideas. SANUWAVE is excited to represent and share our innovative dermaPACEA® technology and how it uniquely contributes to present day wound healing solutions.a??A About SANUWAVE Health, Inc.SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVEa??s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the bodya??s normal healing processes and regeneration. SANUWAVE applies its patented PACEA® technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACEA®, is US FDA cleared for the treatment of Diabetic Foot Ulcers.A  The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTronA®A device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, EvotronA®A and orthoPACEA®A devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVEa??s shock wave technology for non-medical uses, including energy, water, food and industrial markets.Forward-Looking StatementsThis press release may contain a??forward-looking statementsa?? within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Companya??s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Companya??s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Companya??s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Companya??s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.For additional information about the company, visitA www.SANUWAVE.com.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2018    »
ПнВтСрЧтПтСбВс
 12
3456789
10111213141516
17181920212223
24252627282930
31